Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients.
about
Pharmacogenetic studies update in type 2 diabetes mellitusPharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agentsCoexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel.KCNJ11: Genetic Polymorphisms and Risk of Diabetes MellitusPharmacogenomics in diabetes mellitus: insights into drug action and drug discoveryPersonalized medicine in Type 2 DiabetesPharmacogenomics in type 2 diabetes: oral antidiabetic drugs.Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Genetics of type 2 diabetes: insights into the pathogenesis and its clinical application.KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment.Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group.Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms.Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.Clinical translation of genetic predictors for type 2 diabetes.Pharmacogenetics of Anti-Diabetes Drugs.Pharmacogenetics in type 2 diabetes: potential implications for clinical practiceMonogenic models: what have the single gene disorders taught us?Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine.Genetic architecture of type 2 diabetes: recent progress and clinical implicationsCYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patientsThe clinical application of genetic testing in type 2 diabetes: a patient and physician survey.Pharmacogenetics of oral antidiabetic drugs.Pharmacogenetics and personalized treatment of type 2 diabetesPolymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes.The pharmacogenetics of type 2 diabetes: a systematic review.Genetic susceptibility to type 2 diabetes and implications for therapy.The genetics of type 2 diabetes: what have we learned from GWAS?Type 2 diabetes and obesity: genomics and the clinic.The molecular genetics of sulfonylurea receptors in the pathogenesis and treatment of insulin secretory disorders and type 2 diabetes.The genetics of type 2 diabetes and its clinical relevance.Genetics of type 2 diabetes and potential clinical implications.The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?Genetics of drug response in type 2 diabetes.Using Personalized Medicine in the Management of Diabetes Mellitus.Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation.Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers.The Application of Genomics in Diabetes: Barriers to Discovery and Implementation.Association between TCF7L2 Genotype and Glycemic Control in Diabetic Patients Treated with Gliclazide.
P2860
Q26739350-99D68AD9-F268-439A-ACA7-76E24990CE0CQ26751138-1428A6BE-59A0-4C1A-8335-2779D7F75C26Q27865237-BD739AAF-B252-45C7-9181-2AB3E44EA351Q28085471-08AE7AD7-2C8A-4C08-92F8-D16FFBF1BEE8Q28274686-88CBF254-05A4-41C0-8376-13AC8FEC063FQ28542708-768FB4A7-9F6D-4AD6-AB50-9AAF49704AE2Q30248914-C224CFC0-F81D-4BD2-8B39-4BD0D513607FQ30571118-D7BE52B4-D811-4AC9-A78B-3F0836214528Q33593963-D08AE450-F204-415C-80E4-8B83090710BEQ33771570-D74BAE41-121C-4F11-A39E-35043E0392BBQ33790423-B8430618-F060-44FE-9899-488BEA00768AQ33813015-CB2679BA-3D50-4553-A150-C419E31AC2CBQ33993320-C5CB9D64-3EF0-4C3E-B17D-42127B1568E5Q34124681-576DD572-2B49-4726-8F00-DF763B7EBB36Q34181995-D659D4EE-A3DB-4A50-B5EB-7448B6AC35B9Q35840645-D298684C-A87E-4E0D-9DBE-AD3EA5C0B2F2Q36369882-009A8CC0-1538-4A91-8996-C33855FFD31AQ36441465-1695C0DE-C761-4A43-AE19-2B5644F2BC1DQ37189221-664BC5CC-D7D4-4D17-B9A1-61D85ED29E13Q37227417-927E674A-9065-43B1-BEDF-BC47F66B1BA3Q37312908-8B7605E5-4F42-4B22-827C-CDA7881F9B44Q37353476-4E74C7F5-F4F8-4194-9C2D-CF8A854EDE87Q37508445-30FF6F49-F5FA-4A91-A13F-74F1EA1C2AB2Q37571899-BB32C8E9-ED07-42E4-9216-BD8E797B2999Q37597017-86433E67-7C91-41DD-BE64-7040BF02799FQ37689851-9A475C73-28D4-4022-8586-AB6FAF7018BAQ37811045-BC6848B8-1EB7-4E7F-9222-02DE3F095BFAQ37885799-841D2CE0-CB15-4283-A25A-35072C9DE6D8Q37942030-6BFB0579-1DA9-4A6B-AE78-EAABC63D7D97Q38061186-52921D81-9415-4E1F-9C35-BF35C9B3008EQ38078821-0328679B-06AC-41E7-B7CD-70318F40C2E7Q38110432-17781EC1-C863-41E2-9917-0601F6E82680Q38270699-443F4D5B-03EC-46B7-9087-50D6D9C48B93Q38480670-5DC2AE5B-3232-4193-A04E-C2FC5B21D800Q38666166-7D1A437A-E14A-48EF-AA03-D8DE21273246Q38711541-6B4D57D6-13E6-4F91-84BA-7CBD8FAEAA40Q38747416-8664985F-FB22-44C3-BBF3-3A7174B0C24CQ38831752-D594CCAF-0910-4605-9E68-F60BE3F08FF8Q39123582-A68E454F-418E-4EE4-A329-14DD72A90FCCQ41505625-F36221F4-6DEF-4230-97CF-FF9758C09E6F
P2860
Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Ser1369Ala variant in sulfonyl ...... nese type 2 diabetic patients.
@en
type
label
Ser1369Ala variant in sulfonyl ...... nese type 2 diabetic patients.
@en
prefLabel
Ser1369Ala variant in sulfonyl ...... nese type 2 diabetic patients.
@en
P2093
P2860
P356
P1433
P1476
Ser1369Ala variant in sulfonyl ...... nese type 2 diabetic patients.
@en
P2093
Genfu Tang
Guangyun Mao
Houxun Xing
Jinqui Yang
Lirong Sun
Weiqing Ma
Xiaobin Wang
Xiaowei Ren
P2860
P304
P356
10.2337/DC07-2248
P407
P577
2008-07-03T00:00:00Z